$2.18
▲ +4.6% Today
as of Oct 23, 16:49 ET
Last 30 days
Recent Press Releases & News
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia
HURA earnings at a glance
Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±4.6% on average; after the most recent report on May 15, 2026 it moved -8.0%. HURA beat the consensus EPS estimate in 1 of its last 4 reported quarters. The share price of $2.18 sits in the middle of its 52-week range.
Overview
52-week range
$0.41
$3.43
59% of range
Avg surprise (last 4)
-19.2%
Avg reaction (last 2)
-4.6%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.14 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.13 | $-0.11 | -18.2% | +13.3% | -8.0% | earnings |
| Fri Nov 14, 2025 | Sep/2025 | $-0.14 | $-0.15 | +6.7% | — | — | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-0.21 | $-0.14 | -50.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.15 | $-0.13 | -15.4% | — | -1.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.54 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.43 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.40 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — | $0 | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $-9M | $-8M | — | $-7M | $-10M | $-7M | — | $-6M |
| EPS (diluted) | $-0.14 | $-0.13 | — | $-0.14 | $-0.21 | $-0.15 | — | $-0.54 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $995,977 | $6M | $4M | $3M | $9M | $6M | $13M | $3M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $2M | $7M | $5M | $4M | $13M | $14M | $20M | $3M |
| Total assets | $32M | $30M | $27M | $26M | $35M | $15M | $20M | $4M |
| Long-term debt | $4M | — | — | — | — | — | — | — |
| Total liabilities | $13M | $7M | $6M | $9M | $15M | $5M | $5M | $2M |
| Total equity | $19M | $23M | $21M | $17M | $19M | $10M | $15M | $-3M |
Implied volatility — last 90 days
No IV snapshots yet for HURA.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
SPRB
Spruce Biosciences, Inc.
$129M
$45.15+5.7%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$123M
$4.05-5.5%
PMVP
PMV Pharmaceuticals, Inc.
$132M
$1.27-6.6%
AARD
Aardvark Therapeutics, Inc.
$115M
$1.39-68.5%
LIXT
Lixte Biotechnology Holdings, Inc.
$115M
$7.21+75.8%
GNLX
Genelux Corporation
$114M
$2.00-3.4%
HURA earnings FAQ
How does HURA stock usually react to earnings?
Across the last 2 reports the average next-day move was ±4.6%, up 0 times and down 2 times.